Clinical development and the randomized clinical trial (RCT) remain largely unaffected by the unprecedented wave of innovation in pharmaceutical R&D fueled by developments in artificial intelligence (AI), including generative AI (gen AI) and foundational models. However,…
Scott Askin,1,2 Denis Burkhalter,1,2 Gilda Calado,1,3 and Samar El Dakrouni1,4 Author information Article notes Copyright and License information PMC Disclaimer Associated Data Data Availability Statement Abstract Background Clinical Trials (CTs) remain the foundation of safe and effective drug development. Given the evolving…
Dr. Roach: Welcome to “Q&A with FDA,” from the FDA’s Division of Drug Information, where we aim to answer some of the most frequently asked questions that we’ve received from the public. My name is Dr.…
ICON’s 2023 Biotech Survey explores how biotech companies are adapting to significant declines in funding availability. Key data shows 60% plan to increase R&D spend despite constraints, 51% have 4+ active trials, and 93% are…